Apogenix, which spun out from the German Cancer Research Center,  the largest biomedical research institute, raised €7.5m ($9.6m) in a round led by Apogenix investor Dievini Hopp BioTech, the life sciences investment firm of Germany-based software company SAP co-founder Dietmar Hopp.

 The round was also participated in by the German Cancer Research Center. Apogenix is developing protein treatments for cancer and inflammatory diseases.

Apogenix was found in 2005 and has raised more than €50m across three financing rounds. It has also been awarded public funds worth €8.5m.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?